Expanded Pediatric Use for Roflumilast Under FDA Review
If approved, topical roflumilast 0.05% will be approved for treating atopic dermatitis down to age 3 months. Medscape Medical News
Read the full articleYou might also wanna read
Efficacy and Safety of Roflumilast Foam 0.3% in Trial Participants With Seborrheic Dermatitis
Conditions : Seborrheic Dermatitis Interventions : Drug: Roflumilast Foam 0.3%; Drug: Vehicle foam Sponsors : Hangzhou Zhongmei Huadong Phar
Safety and Efficacy of Roflumilast Foam 0.3% in Adolescent and Adult Subjects With Hidradenitis Suppurativa
Conditions : Hidradenitis Suppurativa (HS) Interventions : Drug: Roflumilast 0.3% topical foam Sponsors : Harrison Dermatology Not yet recru
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
Conditions : Moderate-to-Severe Atopic Dermatitis Interventions : Drug: Rezpegaldesleukin; Drug: Placebo Sponsors : Nektar Therapeutics Recr
FDA approves bemotrizinol, first new sunscreen ingredient in over 25 years
Move will give Americans access to a skin-protecting chemical long used in Europe.
denverpost.com·1mo ago
FDA approves bemotrizinol, first new sunscreen ingredient in over 25 years
Federal health regulators have signed off on the first new sunscreen ingredient for the U.S. market in more than 25 years. The announcement
apnews.com·27d ago
New Pediatric Eczema Guidelines Call for Personalized Atopic Dermatitis Treatment
The American Academy of Dermatology (AAD) has released its first evidence-based guidelines for preventing and treating atopic dermatitis, th
Comments
Sign in to join the conversation.
No comments yet. Be the first.